BSX · Boston Scientific Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.20B | - | $5.07B | $5.06B | $4.66B | - | $4.21B | $4.12B | $3.86B | - |
| Cost of Revenue | $1.59B | - | $1.52B | $1.64B | $1.45B | - | $1.31B | $1.27B | $1.21B | - |
| Gross Profit | $3.61B | - | $3.54B | $3.42B | $3.21B | - | $2.90B | $2.85B | $2.65B | - |
| R&D | $516.00M | - | $514.00M | $526.00M | $443.00M | - | $407.00M | $383.00M | $366.00M | - |
| SG&A | $1.78B | - | $1.74B | $1.72B | $1.60B | - | $1.56B | $1.45B | $1.36B | - |
| Total Operating Expenses | $2.51B | - | $2.49B | $2.60B | $2.29B | - | $2.16B | $2.33B | $1.97B | - |
| D&A | $351.00M | - | $117.00M | $111.00M | $325.00M | - | $102.00M | $98.00M | $304.00M | - |
| Operating Income | $1.10B | - | $1.05B | $819.00M | $921.00M | - | $733.00M | $520.00M | $675.00M | - |
| Interest Expense | $90.00M | - | $87.00M | $90.00M | $82.00M | - | $79.00M | $77.00M | $69.00M | - |
| Income Tax | ($176.00M) | - | $183.00M | $146.00M | $133.00M | - | $200.00M | $98.00M | $115.00M | - |
| Net Income | $1.34B | - | $755.00M | $797.00M | $674.00M | - | $469.00M | $324.00M | $495.00M | - |
| EPS - Basic | $0.90 | - | $0.51 | $0.54 | $0.46 | - | $0.32 | $0.22 | $0.34 | - |
| EPS - Diluted | $0.90 | - | $0.51 | $0.53 | $0.45 | - | $0.32 | $0.22 | $0.33 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.45B | $1.97B | $1.27B | $534.00M | $725.00M | $414.00M | $2.50B | $2.91B | $2.33B | $865.00M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $3.12B | $2.94B | $2.92B | $2.86B | $2.87B | $2.81B | $2.75B | $2.61B | $2.56B | $2.48B |
| Accounts Payable | $1.14B | $1.14B | $1.00B | $962.00M | $1.00B | $960.00M | $907.00M | $906.00M | $921.00M | $942.00M |
| Current Assets | $8.68B | $8.79B | $8.04B | $7.12B | $7.33B | $6.92B | $8.76B | $8.99B | $8.19B | $6.51B |
| Total Assets | $44.35B | $43.67B | $42.71B | $41.56B | $40.14B | $39.40B | $38.08B | $37.11B | $36.67B | $35.14B |
| Current Liabilities | $4.57B | $5.44B | $5.33B | $5.19B | $5.06B | $6.40B | $5.91B | $5.58B | $4.92B | $4.93B |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $25.86B | $24.23B | $23.39B | $22.42B | $22.21B | $21.77B | $20.71B | $20.37B | $19.93B | $19.28B |
| Retained Earnings | $6.91B | $5.57B | $4.90B | $4.14B | $3.35B | $2.67B | $2.11B | $1.64B | $1.31B | $819.00M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $348.00M | - | - | - | $541.00M | - | - | - | $164.00M | - |
| Investing Cash Flow | ($591.00M) | - | - | - | ($500.00M) | - | - | - | ($285.00M) | - |
| Financing Cash Flow | ($260.00M) | - | - | - | $233.00M | - | - | - | $1.57B | - |
| CapEx | $177.00M | - | - | - | $187.00M | - | - | - | $179.00M | - |
| Free Cash Flow | $171.00M | - | - | - | $354.00M | - | - | - | ($15.00M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 69.5% | - | 69.9% | 67.7% | 68.8% | - | 68.8% | 69.2% | 68.7% | - |
| Operating margin | 21.2% | - | 20.7% | 16.2% | 19.8% | - | 17.4% | 12.6% | 17.5% | - |
| EBITDA margin | 27.9% | - | 23.0% | 18.4% | 26.7% | - | 19.8% | 15.0% | 25.4% | - |
| Net margin | 25.8% | - | 14.9% | 15.7% | 14.5% | - | 11.1% | 7.9% | 12.8% | - |
| Free cash flow margin | 3.3% | - | - | - | 7.6% | - | - | - | -0.4% | - |
| FCF / Net income | 0.13 | - | - | - | 0.53 | - | - | - | -0.03 | - |
| R&D / Revenue | 9.9% | - | 10.1% | 10.4% | 9.5% | - | 9.7% | 9.3% | 9.5% | - |
| SG&A / Revenue | 34.2% | - | 34.4% | 33.9% | 34.2% | - | 37.1% | 35.1% | 35.4% | - |
| Effective tax rate | -15.1% | - | 19.5% | 15.5% | 16.5% | - | 29.9% | 23.2% | 18.9% | - |
| Return on assets | 3.0% | - | 1.8% | 1.9% | 1.7% | - | 1.2% | 0.9% | 1.3% | - |
| Return on equity | 5.2% | - | 3.2% | 3.6% | 3.0% | - | 2.3% | 1.6% | 2.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.90 | 1.62 | 1.51 | 1.37 | 1.45 | 1.08 | 1.48 | 1.61 | 1.66 | 1.32 |
| Quick ratio | 1.22 | 1.08 | 0.96 | 0.82 | 0.88 | 0.64 | 1.02 | 1.14 | 1.14 | 0.82 |
| Cash ratio | 0.32 | 0.36 | 0.24 | 0.10 | 0.14 | 0.06 | 0.42 | 0.52 | 0.47 | 0.18 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 12.2x | - | 12.0x | 9.1x | 11.2x | - | 9.3x | 6.8x | 9.8x | - |
| Equity multiplier | 1.71 | 1.80 | 1.83 | 1.85 | 1.81 | 1.81 | 1.84 | 1.82 | 1.84 | 1.82 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | - | 0.12 | 0.12 | 0.12 | - | 0.11 | 0.11 | 0.11 | - |
| Inventory turnover | 0.51 | - | 0.52 | 0.57 | 0.51 | - | 0.48 | 0.49 | 0.47 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 716d | - | 700d | 638d | 720d | - | 766d | 750d | 773d | - |
| Days payable outstanding | 262d | - | 240d | 214d | 252d | - | 252d | 260d | 278d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 69.7x | - | 191.4x | 202.7x | 224.2x | - | 261.9x | 350.0x | 207.5x | - |
| P / B | 3.6x | - | 6.2x | 7.2x | 6.8x | - | 6.0x | 5.6x | 5.1x | - |
| P / S | 18.0x | - | 28.8x | 31.7x | 32.3x | - | 29.6x | 27.7x | 26.3x | - |
| EV / EBITDA | 63.6x | - | 124.2x | 171.9x | 120.3x | - | 146.3x | 180.2x | 101.3x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 11.6% | - | 20.3% | 22.8% | 20.9% | - | 19.3% | 14.5% | 13.8% | - |
| Revenue CAGR (3y) | 15.4% | - | 16.9% | 16.0% | 15.5% | - | 12.8% | 10.2% | 11.9% | - |
| Revenue CAGR (5y) | 13.6% | - | 13.8% | 20.4% | 12.9% | - | 9.2% | 9.4% | 9.1% | - |
| Gross profit growth (YoY) | 12.6% | - | 22.3% | 20.1% | 21.2% | - | 19.4% | 12.1% | 12.7% | - |
| Operating income growth (YoY) | 19.5% | - | 43.0% | 57.5% | 36.4% | - | 5.8% | 1.2% | 22.3% | - |
| Net income growth (YoY) | 99.0% | - | 61.0% | 146.0% | 36.2% | - | -7.1% | 20.0% | 57.6% | - |
| EPS growth (YoY) | 100.0% | - | 59.4% | 140.9% | 36.4% | - | -5.9% | 22.2% | 57.1% | - |
| EPS CAGR (3y) | 62.4% | - | 62.0% | 46.1% | 85.9% | - | 4.6% | 22.4% | 12.8% | - |
| EPS CAGR (5y) | 31.4% | - | - | - | 114.1% | - | 28.9% | 14.9% | 1.9% | - |
| FCF growth (YoY) | -51.7% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | -3.9% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 16.4% | 11.3% | 13.0% | 10.0% | 11.5% | 12.9% | 9.6% | 18.1% | 11.6% | 9.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$20.07B totalCardiovascular$13.25B · 66.0%
Medsurg$6.82B · 34.0%
Product / service
$12.87B totalElectrophysiology EP$2.31B · 18.0%
Interventional Cardiology Vascular Therapies$2.01B · 15.6%
Global Urologyand Pelvic Health Reporting Unit$2.00B · 15.5%
Global Endoscopy Endo Reporting Unit$1.80B · 14.0%
Watchman$1.79B · 13.9%
Cardiac Rhythm Management$1.43B · 11.1%
Global Neuromodulation Nm Reporting Unit$914.00M · 7.1%
Interventional Oncology Embolization$615.00M · 4.8%
Geographic
$17.02B totalUS$4.71B · 27.7%
EMEA$3.45B · 20.3%
Asia Pacific$3.08B · 18.1%
Emerging Markets$2.98B · 17.5%
Non Us$2.11B · 12.4%
Latin Americaand Canada$678.00M · 4.0%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing BOSTON SCIENTIFIC CORP against the 5 most active filers in the same SIC group.